An autoimmune disease drug from Roche and Chugai Pharmaceutical hit its main goal in a closely watched trial, but the results of the study, in a condition called myasthenia gravis, “did not reach our expectations,” the companies said Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,